De Novo Submission Made for Flu Molecular Test
Cue Health has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue Flu Molecular Test.
Read MorePosted by Chris Wolski | Sep 2, 2022 | POC Rapid Assays |
Cue Health has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue Flu Molecular Test.
Read MorePosted by Chris Wolski | Sep 2, 2022 | Covid 19 |
MicroGEM and AiTmed have announced the MicroGEM Sal6830 SARS-CoV-2 Saliva Test is now available to AiTmed’s network of healthcare providers.
Read MorePosted by Tonya Manning | Sep 1, 2022 | Podcasts |
Of all the changes caused by the COVID-19 pandemic, the evolution of POC and home testing is perhaps the biggest. CLP Director of Business Intelligence Chris Wolski and Hamid Erfanian, CEO of Enzo Biochem, an integrated healthcare company focused on offering life sciences, including reagents, clinical testing and molecular diagnostic products, do a deep dive on the history of POC testing, how and why it became ubiquitous during COVID-19, and what this ubiquity means for the future of the clinical laboratory.
Read MorePosted by Andy Lundin | Aug 31, 2022 | Stroke |
A person’s blood type may be linked to their risk of having an early stroke, according to a new meta-analysis from UMSOM researchers.
Read MorePosted by Andy Lundin | Aug 30, 2022 | Covid 19 |
Cue Health announced the nationwide launch of Cue Care, its same-day, at-home, test-to-treatment solution.
Read More